A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
22 mai 2024 10h23 HE
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.
YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
21 mai 2024 08h00 HE
|
Y-Prime, LLC
YPrime's new glucometer/eCOA functionality offers a patient-centric, intuitive, and connected experience to clinical trial participants.
HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
15 mai 2024 12h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 mai 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
New YPrime Report Highlights eCOA's Impact on CNS Trials
01 mai 2024 08h00 HE
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
30 avr. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
22 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-upAll Patients Have Either Stabilized or Improved on Nasal...
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27 mars 2024 23h43 HE
|
Indegene Inc
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease
26 mars 2024 14h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in AI-driven healthcare technology, today announced the launch of the DECIDE Registry, the largest prospective...
HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography
12 mars 2024 09h00 HE
|
HeartFlow Holding, Inc.
HeartFlow's non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) --...